JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

G. Barosi; C. Klersy; L. Villani; E. Bonetti; P. Catarsi; V. Poletto; R. Campanelli; S. Impera; R. Latagliata; G. Viarengo; A. Carolei; M. Massa; M. Musso; A. Crescimanno; R. P. Gale; V. Rosti

doi:10.1038/leu.2016.45

JAK2^V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

G. Barosi, C. Klersy, L. Villani, E. Bonetti, P. Catarsi, V. Poletto, R. Campanelli, S. Impera, R. Latagliata, G. Viarengo, A. Carolei, M. Massa, M. Musso, A. Crescimanno, R. P. Gale, V. Rosti

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Leukemia
DOIs	https://doi.org/10.1038/leu.2016.45
Publication status	Accepted/In press - Feb 29 2016

ASJC Scopus subject areas

Hematology
Cancer Research
Anesthesiology and Pain Medicine

Access to Document

10.1038/leu.2016.45

Cite this

Barosi, G., Klersy, C., Villani, L., Bonetti, E., Catarsi, P., Poletto, V., Campanelli, R., Impera, S., Latagliata, R., Viarengo, G., Carolei, A., Massa, M., Musso, M., Crescimanno, A., Gale, R. P., & Rosti, V. (Accepted/In press). JAK2^V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. Leukemia. https://doi.org/10.1038/leu.2016.45

Barosi, G, Klersy, C , Villani, L, Bonetti, E, Catarsi, P, Poletto, V, Campanelli, R, Impera, S, Latagliata, R, Viarengo, G , Carolei, A , Massa, M, Musso, M, Crescimanno, A, Gale, RP & Rosti, V 2016, 'JAK2^V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy', Leukemia. https://doi.org/10.1038/leu.2016.45

@article{04fa4ffafb004ef99df1e88bef6437fe,

title = "JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy",

author = "G. Barosi and C. Klersy and L. Villani and E. Bonetti and P. Catarsi and V. Poletto and R. Campanelli and S. Impera and R. Latagliata and G. Viarengo and A. Carolei and M. Massa and M. Musso and A. Crescimanno and Gale, {R. P.} and V. Rosti",

year = "2016",

month = feb,

day = "29",

doi = "10.1038/leu.2016.45",

language = "English",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

AU - Barosi, G.

AU - Klersy, C.

AU - Villani, L.

AU - Bonetti, E.

AU - Catarsi, P.

AU - Poletto, V.

AU - Campanelli, R.

AU - Impera, S.

AU - Latagliata, R.

AU - Viarengo, G.

AU - Carolei, A.

AU - Massa, M.

AU - Musso, M.

AU - Crescimanno, A.

AU - Gale, R. P.

AU - Rosti, V.

PY - 2016/2/29

Y1 - 2016/2/29

UR - http://www.scopus.com/inward/record.url?scp=84961226182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961226182&partnerID=8YFLogxK

U2 - 10.1038/leu.2016.45

DO - 10.1038/leu.2016.45

M3 - Article

AN - SCOPUS:84961226182

SN - 0887-6924

JO - Leukemia

JF - Leukemia

ER -

JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

JAK2^V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy